First Line Trials

 
        ClinicalTrials.gov Identifier:                 NCT04035486        

This study is active but not recruiting participants. 
 
The reason for the study is to find out if an experimental combination of an oral medication called osimertinib (TAGRISSO®) when used in combination with chemotherapy is more effective than giving osimertinib alone for the treatment of locally advanced or metastatic non-small cell lung cancer.

Alberta
Calgary
Edmonton

Ontario
Toronto
 
Quebec
Montreal

       ClinicalTrials.gov Identifier:              NCT04619797      

This study is currently recruiting participants. 
 
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of tiragolumab in combination with atezolizumab plus pemetrexed and carboplatin/cisplatin (Arm A) compared with placebo in combination with pembrolizumab plus pemetrexed and carboplatin/cisplatin (Arm B) in participants with previously untreated, locally advanced unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC).

Alberta
Cross Cancer Institute, Edmonton
 
Ontario
Royal Victoria Regional Health Centre, Barrie
Victoria Hospital - London Health Sciences Centre, London
Lakeridge Health, Oshawa
Sault Area Hospital, Sault Ste Marie
Princess Margaret Cancer Centre, Toronto
 
Quebec
Universite de Montreal - Hopital Maisonneuve-Rosemount, Montreal

3. Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrilizumab (MK-3475) with or without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults with Metastatic Nonsquamous NSCLC (MK-7902-006/E7080-G000-315/LEAP-006)

         ClinicalTrials.gov Identifier:                    NCT03829319          

This study is active but not recruiting participants
 
The purpose of this study is to assess the safety and efficacy of pemetrexed + platinum chemotherapy + pembrolizumab (MK-3475) with or without lenvatinib (MK-7902/E7080) as first-line intervention in adults with metastatic nonsquamous non-small cell lung cancer.

Ontario
Juravinski Cancer Centre (Site 0407), Hamilton
Kingston Health Sciences Centre (Site 0414), Kingston
Lakerrdge Health (Site 0406), Oshawa
Sault Area Hospital (Site 0413), Sault Ste Marie

Quebec
Hopital Cite de la Sante de Laval (Site 0400), Laval
CIUSSS l'Ouest de l'Ile de Montreal - St-Marys Hospital (Site 0412), Montreal
CIUSSS de la Mauricie et du Centre du Quebec (Site 0408), Trois-Rivieres  
CHU de Quebec - Universite Laval - Hotel Dieu de Quebec (Site 0403), Quebec  

4. Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100)

           ClinicalTrials.gov Identifier:                    NCT02576574        

This study is active but not currently recruiting.

The purpose of this study is to demonstrate superiority with regard to progression free survival (PFS) based on an Independent Review Committee (IRC) assessment of avelumab versus platinum-based doublet in non-small cell lung cancer (NSCLC) subjects with Programmed death ligand 1+ (PD-L1+) tumours.

New Brunswick 
The Moncton Hospital
Moncton, New Brunswick, Canada, E1C 6Z8

Ontario
Mount Sinai Hospital
Toronto, Ontario, Canada, M5G 1X5

 

5. A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer(NSCLC) (B-FAST)

         ClinicalTrials.gov Identifier:                    NCT03178552         

This study is currently recruiting participants. 

This is a phase 2/3, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in combination in participants with unresectable, advanced or metastatic NSCLC determined to harbor oncogenic somatic mutations or positive by tumor mutational burden (TMB) assay as identified by two blood-based next-generation sequencing (NGS) circulating tumor DNA (ctDNA) assays.

Alberta
Cross Cancer Institute, Edmonton                                                                           Recruiting

Ontario 
Royal Victoria Regional Health Centre; c/o Oncology Clinical Trials       Recruiting
Barrie, Ontario, Canada, L4M 6M2
 
William Osler Health System Brampton Civic Hospital       Recruiting
Brampton, Ontario, Canada, L6R 3J7
 
London Health Sciences Centre · Victoria Hospital; Department of Medicine       Recruiting
London, Ontario, Canada, N6A 5W9
 
Lakeridge Health Center; R. S. MacLaughlin Durham Regional Cancer Center       Recruiting
Oshawa, Ontario, Canada, L1G 2B9
 
Sunnybrook Health Sciences Centre        Recruiting
Toronto, Ontario, Canada, M4N 3M5
 
Princess Margaret Hospital; Medical Oncology Dept       Recruiting
Toronto, Ontario, Canada, M5G 2M9

Quebec
Jewish General Hospital; Sir Mortimer B. Davis                                                       Recruiting
Montreal, Quebec, Canada, H2W 1S6
 
IUCPQ (Hôpital Laval)                                                                                              Recruiting
Quebec City, Quebec, Canada, G1V 4G5

Saskatchewan 
Saskatoon Cancer Agency                                                                                       Recruiting
Saskatoon, Saskatchewan, Canada, SK S7N 4H
 
Manitoba 
CancerCare Manitoba; Department of Medical Oncology                                       Recruiting
Winnipeg, Manitoba, Canada, R3E 0V9
 

6. A Study of Atezolizumab Compared With Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Containing Therapy (IPSOS)

        ClinicalTrials.gov Identifier:                  NCT03191786        

This study is active but not currently recruiting. 

This Phase III, global, multicenter, open-label, randomized, controlled study will evaluate the efficacy and safety of atezolizumab (an anti-programmed death-ligand 1 [anti-PD-L1] antibody) compared with a single agent chemotherapy regimen by investigator choice (vinorelbine or gemcitabine) in treatment-naïve participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) who are deemed unsuitable for any platinum-doublet chemotherapy due to poor performance status (Eastern Cooperative Oncology Group [ECOG] performance status of 2-3).
 
New Brunswick
Regional health authority A vitalite health network  
Moncton, New Brunswick, Canada, E1C 8X3
 
Ontario
Ottawa Hospital Research Institute  
Ottawa, Ontario, Canada, K1Y 4E9
 
Sault Area Hospitals  
Sault Ste Marie, Ontario, Canada, P6A 2C4
 
Princess Margaret Cancer Center  
Toronto, Ontario, Canada, M5G 1Z5
 
Quebec
McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology        
Montreal, Quebec, Canada, H3T 1E2
 

7. Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)​

        ClinicalTrials.gov Identifier:                     NCT03515837          

This study is active but not currently recruiting. 
 
The purpose of this study is to evaluate the efficacy and safety of pemetrexed plus platinum chemotherapy (carboplatin or cisplatin) with or without pembrolizumab (MK-3475; KEYTRUDA®) in the treatment of adults with the following types of tyrosine kinase inhibitor (TKI)-resistant, epidermal growth factor receptor (EGFR)-mutated, metastatic non-squamous non-small cell lung cancer (NSCLC) tumors: 1) TKI-failures (including osimertinib [TAGRISSO®] failure) with T790M-negative mutation tumors, 2) T790M-positive mutation tumors with prior exposure to osimertinib, and 3) first-line osimertinib failure regardless of T790M mutation status.

The primary study hypotheses are that the combination of pembrolizumab plus chemotherapy has superior efficacy compared to saline placebo plus chemotherapy in terms of: 1) Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) based on blinded independent central review, and 2) Overall Survival (OS). This study will be considered to have met its success criteria if the combination of pembrolizumab plus chemotherapy is superior to saline placebo plus chemotherapy in terms of PFS or OS.

Ontario
William Osler Health System (Site 0100), Brampton
Sunnybrook Health Sciences, Odette Cancer Centre (Site 0102), Toronto
Princess Margaret Cancer Centre (Site 0104), Toronto
 
Quebec
Jewish General Hospital (Site 0105), Montreal

8. Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Non-small Cell Lung Cancer (NSCLC)(MK-7902-007/E7080-G000-314/LEAP-007)

         ClinicalTrials.gov Identifier:                    NCT03829332          

This study is active but not currently recruiting paricipants. 
 
The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combined with lenvatinib (MK-7902/E7080) compared to pembrolizumab alone (with placebo for lenvatinib) in treatment-naïve adults with no prior systemic therapy for their metastatic non-small cell lung cancer (NSCLC) whose tumors have a programmed cell death-ligand 1 (PD-L1) Tumor Proportion Score (TPS) greater than or equal to 1%.
The primary study hypotheses are that: 1) The combination of pembrolizumab and lenvatinib is superior to pembrolizumab alone as assessed by Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), and 2) The combination of pembrolizumab and lenvatinib is superior to pembrolizumab alone as assessed by Overall Survival (OS).
 
Alberta
Cross Cancer Institute (Site 0400)               
Edmonton, Alberta, Canada, T6G 1Z2
Contact: Study Coordinator, 780-432-8762      
 
Ontario
William Osler Health System (Brampton Civic Hospital) (Site 0402)              
Brampton, Ontario, Canada, L6R 3J7
Contact: Study Coordinator, 905-494-2120 x 58389   
  
Windsor Regional Cancer Program (Site 0404)           
Windsor, Ontario, Canada, N8W 2X3
Contact: Study Coordinator, 519-253-5253      
 

9. A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)

         ClinicalTrials.gov Identifier:                    NCT03516981        

This study is active but not currently recruiting paricipants. 

This study will investigate the utility of biomarker-based triage for study participants with advanced non-small cell lung cancer (NSCLC) without prior systemic therapy. Study participants within groups defined by a biomarker-based classifier (gene expression profile [GEP] and tumor mutational burden [TMB]) will be randomized to receive pembrolizumab in combination with MK-1308, MK-4280, or lenvatinib. The primary hypotheses are as follows: In participants receiving pembrolizumab in combination with either MK-1308, MK-4280, or lenvatinib, the Objective Response Rate (ORR) will be 1) greater than 5% among participants with low GEP and low TMB, 2) greater than 20% among participants with low GEP and high TMB, 3) greater than 20% among participants with high GEP and low TMB, and 4) greater than 45% among participants with high GEP and high TMB.
 
Ontario
Sunnybrook Health Science Centre (Site 0304)              Recruiting
Toronto, Ontario, Canada, M4N 3M5
Contact: Study Coordinator, 416-480-5000 x 7955      


 
Quebec
Jewish General Hospital (Site 0307)              Recruiting
Montreal, Quebec, Canada, H3T 1E2
Contact: Study Coordinator, 514-340-8222 x 23674   
 
 

10. TAK-788 as First-line Treatment vs. Platinum-Based Chemotherapy for NSCLC with EGFR Exon 20 Insertion Mutations

          ClinicalTrials.gov Identifier:                   NCT04129502         
 
This study is currently recruiting participants. 
 
The purpose of this study is to compare the efficacy of TAK-788 as first-line treatment with that of platinum-based chemotherapy in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors harbor epidermal growth factor receptor (EGFR) exon 20 insertion mutations.

British Columbia
BC Cancer Agency, Vancouver

Alberta
Tom Baker Cancer Centre, Calgary

Ontario
William Osler Health System, Brampton
Princess Margaret Hospital, Toronto

Quebec
Hopital du Sacre Coeur de Montreal, Montreal

11. Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer

         ClinicalTrials.gov Identifier                  NCT02414139        

This study is active but not currently recruiting paricipants

A phase II study to evaluate antitumor activity of oral cMET inhibitor INC280 in adult patients with EGFR wild-type, advanced non-small cell lung cancer (NSCLC) as measured by overall response rate (ORR). The study will also evaluate safety and pharmacokinetics of INC280.
 
Nova Scotia
Novartis Investigative Site                              
Halifax, Nova Scotia, Canada, B3H 1V7

Ontario
Novartis Investigative Site                               
Ottawa, Ontario, Canada, K1H 8L6
 
         ClinicalTrials.gov Identifier:                    NCT03302234         
 
This study is active but not currently recruiting. 
 
The purpose of this study is to determine the efficacy of pembrolizumab given in combination with either ipilimumab or placebo as first-line treatment in participants with metastatic non-small cell lung cancer (NSCLC). The primary hypothesis of this study is that overall survival (OS) and/or progression-free survival (PFS) is prolonged in participants who receive pembrolizumab and ipilimumab compared to those who receive pembrolizumab and placebo.
 
Alberta
Tom Baker Cancer Centre (Site 0119)           
Calgary, Alberta, Canada, T2N 4N2
Contact: Study Coordinator, 403-521-3347
     
Manitoba
CancerCare Manitoba (Site 0106)           
Winnipeg, Manitoba, Canada, R3E 0V9
Contact: Study Coordinator, 204-787-8776      
 
Quebec
CIUSSS du Saguenay-Lac-St-Jean (Site 0115)           
Chicoutimi, Quebec, Canada, G7H 5H6
Contact: Study Coordinator, 418-541-1234 x 2840
     
CISSS de la Monteregie-Centre (Site 0100)           
Greenfield Park, Quebec, Canada, J4V 2H1
Contact: Study Coordinator, 450-466-5000 x 3226  
    
CISSS-CA Hotel-Dieu de Levis (Site 0108)   
Levis, Quebec, Canada, G6V 3Z1
Contact: Study Coordinator, 418-835-7121 x 3048   
  
CIUSSS Ouest de l'Ile - St-Mary's Hospital (Site 0107)        
Montreal, Quebec, Canada, H3T 1M5
Contact: Study Coordinator, 514-345-3511 x 3981  
    
St-Jerome Medical Research Inc (Site 0113)    
St-Jerome, Quebec, Canada, J7Z 5T3
Contact: Study Coordinator,  450431102042      
 

13. Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects (CANOPY-1)

         ClinicalTrials.gov Identifier:                 NCT03631199       

This study is active but not curently recruiting. 

This is a phase III study of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab in previously untreated locally advanced or metastatic non-squamous and squamous NSCLC subjects.

The study will assess primarily the safety and tolerability (safety run-in part) of pembrolizumab plus platinum-based doublet chemotherapy with canakinumab and then the efficacy (double-blind, randomized, placebo controlled part) of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab.

Ontario 
Novartis Investigative Site                                 
Toronto, Ontario, Canada, M5G 1Z6
 
Novartis Investigative Site
Toronto, Ontario, Canada, M5G 1Z6

Alberta
Novartis Investigative Site
Edmonton, Alberta, Canada, T6G 1Z2

14. A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

        ClinicalTrials.gov Identifier:                  NCT03052608         

This study is active but not curently recruiting. 

A phase 3 study to demonstrate whether lorlatinib given as monotherapy is superior to crizotinib alone in prolonging the progression-free survival in advanced ALK-positive NSCLC patients who are treatment naïve and to compare lorlatinib to crizotinib with respect to overall survival in the same population.

Ontario
Princess Margaret Cancer Centre                             
Toronto, Ontario, Canada, M5G 2M9

Quebec
McGill University Health Centre                                
Montreal, Quebec, Canada, H4A 3J1

15. A Study of Selpercatinib (LY3527723) in Participants with Advanced or Metastatic RET Fusion-Positive NSCLC (LIBRETTO-431)

        ClinicalTrials.gov Identifier:                  NCT04194944      
 
This study is currently recruiting participants. 
 
The reason for this study is to see if the study drug selpercatinib compared to a standard treatment is effective and safe in participants with rearranged during transfection (RET) fusion-positive non-squamous non-small cell lung cancer (NSCLC) that has spread to other parts of the body. Participants who are assigned to the standard treatment and discontinue due to progressive disease have the option to potentially crossover to selpercatinib.

Alberta
Cross Cancer Institute

Ontario
Princess Margaret Hospital, Toronto

 

16. A Study of Novel Anti-cancer Agents in Patients with Previously Untreated NSCLC (MAGELLAN)

 
        ClinicalTrials.gov Identifier:                  NCT03819465     
 
This study is active but not curently recruiting.
 
This study is designed to determine the efficacy and safety of durvalumab and/or novel oncology therapies, with or without chemotherapy, for first-line Stage IV Non-Small Cell Lung Cancer (NSCLC)

Alberta
Edmonton

Ontario
Ottawa
Toronto

17. A Study of Amivantamab and Lazertinib Combination Therapy vs. Osimertinib in Locally Advanced or Metastatic NSLC (MARIPOSA)

        ClinicalTrials.gov Identifier:                  NCT04487080     

This study is currently recruiting participants. 
 
The purpose of this study is to assess the efficacy of the amivantamab and lazertinib combination, compared with osimertinib, in participants with epidermal growth factor receptor (EGFR) mutation (Exon 19 deletions [Exon 19del] or Exon 21 L858R substitution) positive, locally advanced or metastatic non-small cell lung cancer (NSCLC).

Ontario
Ottawa Hospital, Ottawa
Sunnybrook Cancer Centre, Toronto
Juravinski Cancer Centre, Hamilton

Quebec
McGill University Hospital, Montreal
 

18. A Study of Combination Amivantamab and Carboplatin-Permetrexed Therapy, Compared with Carboplatin-Permetrexed, in Participants with Advanced or Metastatic NSCLC Characterized by EGFR Exon 20 Insertions (PAPILLON)

        ClinicalTrials.gov Identifier:                  NCT04538664      
 
This study is currently recruiting participants. 
 
The purpose of this study is to compare the efficacy, as demonstrated by progression-free survival (PFS), in participants treated with amivantamab in combination with chemotherapy, versus chemotherapy alone in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) characterized by EGFR Exon 20ins mutations.

Alberta
Edmonton

Ontario
Ottawa Hospital, Ottawa
Sunnybrook Cancer Centre, Toronto

Quebec
McGill Universtiy Health Centre, Montreal

 

19. Study of Pembrolizumab (MKL-3475) with or without Maintenance Olaparib in Frist-line Metastatic Squamous NSCLC (MK-7339-008/KEYLINK-008)

 
        ClinicalTrials.gov Identifier:                  NCT03976362      
 
This study is active but not curently recruiting.
 
The current study will compare pembrolizumab (MK-3475) plus maintenance olaparib, vs. pembrolizumab plus maintenance olaparib placebo for the treatment of squamous NSCLC.
 

Nova Scotia
Nova Scotia Health Authority (Site 0103), Halifax

Ontario
Juravinski Cancer Centre (Site 0107), Hamilton
Kingston Health Sciences Centre (Site 0102), Kingston
Stronach Regional Cancer Centre (Site 0100), Newmarket

Quebec
CISSS de la Monteregie-Centre (Site 0101), Greenfield Park
Hopital Cite de la Sante de Laval (Site 0105), Laval
CIUSSS Ouest de l'Ile - St Mary's Hospital, Montreal
CIUSSS de la Mauricie et du Centre du Quebec (Site 0106), Trois-Rivieres 
 

20. Study of Pembrolizumab with Concurrent Chemorasiation Therapy Followed by Pembrolizumab with or without Olaparib in Stage III NSCLC (MK-7339-012/KEYLYNK-012)

        ClinicalTrials.gov Identifier:                  NCT04380636       
 
This study is currently recruiting participants.

The purpose of this study is to assess the efficacy and safety of pembrolizumab in combination with concurrent chemoradiation therapy followed by either pembrolizumab with olaparib placebo (Arm 1) or with olaparib (Arm 2) compared to concurrent chemoradiation therapy followed by durvalumab (Arm 3) in participants with unresectable, locally advanced NSCLC.

Quebec
Centre Hopitalier de l'Universite de Montreal - CHUM, Montreal

 

21. An Open-Label, Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Stage IV Non-Small Cell Lung Cancer (NSCLC) (CheckMate 227)

        ClinicalTrials.gov Identifier:                  NCT02477826       
 
This study is active but not curently recruiting. 

An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC).
The purpose of this study is to show that nivolumab, or nivolumab plus ipilimumab, or nivolumab plus platinum-doublet chemotherapy improves progression free survival and/or overall survival compared with chemotherapy in subjects advanced lung cancer.

AB
Cross Cancer Institute, Edmonton
NL
St. John’s NL
ON
London
QC
Montreal
Rimouski
Trois Rivieres
SK
Regina
Saskatoon
 

22. Trial of BMS-986012 in Combination With Platinum and Etoposide

        ClinicalTrials.gov Identifier:                  NCT02815592      
 
This study is active but not curently recruiting
 
The purpose of this this study is to administer BMS-986012 in Combination with Platinum and Etoposide as First-line Therapy in Extensive Small Cell Lung Cancer.

Alberta
Local Institution
Edmonton, T6G 1Z2
Contact: Site 0005   
 
Ontario
Local Institution
Ottawa,  K1H 8L6
Contact: Site 0008   
     
Local Institution
Toronto,  M5G 2M9
Contact: Site 0006  

  

23. A Study of Nivolumab and Ipilimumab in Untreated Patients With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be  Remoed by Surgery (CheckMate73L)

        ClinicalTrials.gov Identifier:                  NCT04026412      
 

This study is currently recruiting participants.
 
The primary purpose of the study is to compare the effectiveness of nivolumab plus concurrent chemoradiotherapy (CCRT) followed by nivolumab plus ipilimumab (Arm A) vs CCRT followed by durvalumab (Arm C) in participants with untreated Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)

Ontario
Kingston
London
Oshawa
Windsor

Quebec
CISSS du Bas-Saint Laurent Hopital Regional de Rimouski
Troid-Rivieres
 

24Study of Binimetinib in Combination With Pembrolizumab in Advanced Non-Small Cell Lung Cancer

        ClinicalTrials.gov Identifier:                  NCT03991819    
 

This study is currently recruiting participants.
 
This is a Phase I/Ib study whose purpose is to find out if combining an experimental drug called binimetinib with pembrolizumab is beneficial in people who have advanced non-small cell lung cancer. This study may also see if the combination is safe and may also find the best dose of binimetinib that should be added to pembrolizumab.

Ontario
Princess Margaret Cancer Centre, Toronto
 

25Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer

        ClinicalTrials.gov Identifier:                  NCT03793179    
 

This study is currently recruiting participants.
 
This phase III trial studies whether pembrolizumab alone as a first-line treatment, followed by pemetrexed and carboplatin with or without pembrolizumab after disease progression is superior to induction with pembrolizumab, pemetrexed and carboplatin followed by pembrolizumab and pemetrexed maintenance in treating patients with stage IV non-squamous non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as pemetrexed and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving first-line pembrolizumab followed by pemetrexed and carboplatin with or without pembrolizumab works better in treating patients with non-squamous non-small cell cancer.

Alberta
Calgary
Edmonton

British Colombia
Surrey
Vancouver

New Brunswick
Saint John

Ontario
Kingston 
St. Catherines
Thunder Bay
Toronto

Prince Edward Island
Charlottetown

Quebec
Montreal
Quebec City

 

26. A Phase II Study of Durvalumab

        ClinicalTrials.gov Identifier:                  NCT03847649    
 

This study is currently recruiting participants.
 

I238A: The purpose of this study is to find out what effects being treated with durvalumab has on cancer. The researchers doing this study also want to evaluate if prednisone (a type of steroid), when given together with durvalumab, can reduce any side effects.

I238B: The purpose of this study is to allow patients previously enrolled on a completed CCTG trial to continue treatment with durvalumab (+/- tremelimumab)


Alberta
Edmonton

British Colombia
Kelowna

New Brunswick
Saint John

Ontario
Hamilton
Kitchener
Ottawa
Toronto
Windsor

Quebec
Montreal

Saskatchewan 
Saskatoon

27. An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE)

        ClinicalTrials.gov Identifier:                  NCT04563338    
 

This study is currently recruiting participants.
 

This study is being done to look at how effective the drug, atezolizumab, with or without the drug bevacizumab, is for people with inoperable liver cancer or non-small lung cancer that has spread to the liver. This will be done by looking at the duration of time from starting the study drug(s) until the cancer worsens in study participants.

This study will collect blood and tumor tissue samples from participants to look at changes to their tumor(s) before and after receiving atezolizumab and/or bevacizumab.


Ontario
Princess Margaret Cancer Centre, Toronto
 

28. Study of Nivolumab-Ipilimumab and cfDNA in Lung Cancer (ATLAS)

        ClinicalTrials.gov Identifier:                  NCT04966676   
 

This study is currently recruiting participants.
 

The purpose of this research study is to look at how effective two drugs, nivolumab and ipilimumab, are for people with non-small lung cancer that has metastasized (has spread to other parts of the body) and to see what effects these drugs have on these tumors.


Ontario
Princess Margaret Cancer Centre, Toronto
 

29. Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

        ClinicalTrials.gov Identifier:                  NCT03645928   
 

This study is currently recruiting participants.

A prospective, open-label, multi-cohort, non-randomized, multicenter Phase 2 study evaluating adoptive cell therapy (ACT) with TIL LN-144 (Lifileucel)/LN-145 in combination with checkpoint inhibitors or TIL LN-144 (Lifileucel)/LN-145/LN-145-S1 as a single agent therapy.

Ontario
Princess Margaret Cancer Centre, Toronto
 

 

30. Study of Crizotinib for ROS1 and MET Activated Lung Cancer

      ClinicalTrials.gov Identifier:             NCT04084717      

This study is currently active and recruiting participants
 
This is a phase 2 study of a drug called crizotinib in people with metastatic (the cancer has spread to other parts of the body) non-small cell lung cancer with a mutation (change) in genes called ROS1 or MET. The purpose of this study is to look at how effective crizotinib is at treating ROS1 or MET mutated non-small cell lung cancer.

Crizotinib, also called XALKORI, is a chemotherapy drug that is currently approved for the treatment of ALK- or ROS1- positive advanced non-small cell lung cancer.

Ontario
Princes Margaret Hospital, Toronto

31. APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA)

      ClinicalTrials.gov Identifier:             NCT03175224     

This study is currently active and recruiting participants
 

The primary Phase 1 purpose of this study was to assess overall safety, tolerability and recommended Phase 2 dose (RP2D) of APL-101.

The Phase 2 portion will assess efficacy of the dose determined in Phase 1 in individuals with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations; individuals with cancers associated with c-Met amplifications; individuals with cancers associated with c-Met fusion


Alberta
Edmonton
Manitoba
Winnipeg
Ontario
Toronto
Quebec
Montreal
 

32. A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

      ClinicalTrials.gov Identifier:             NCT04449874   

This study is currently active and recruiting participants
 

This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.


Ontario
Ottawa
Toronto

Quebec
Montreal
 

33. Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer With Osimertinib Third-line Rechallenge (OCELOT)

      ClinicalTrials.gov Identifier:              NCT04335292     
 
This study is currently recruiting participants.
 

This phase II single-armed study will examine the clinical utility of retreating patients with osimertinib, in the third-line, following first-line treatment with osimertinib and second-line treatment with platinum and pemetrexed chemotherapy. The current standard of care for first-line Epidermal Growth Factor Receptor (EGFR) mutated Advanced Non-Small Cell Lung Cancer (aNSCLC) is osimertinib, followed by cytotoxic chemotherapy.

The repeat of osimertinib following previous treatment failure is investigational, although supported by scientific rationale. The dosing and scheduling of osimertinib follows its use in approved settings. The investigators examine its tolerability and efficacy in this setting to ensure osimertinib is a safe third-line option for patients with Epidermal Growth Factor Receptor mutated (EGFR+) Advanced Non-Small Cell Lung Cancer(aNSCLC).


British Colombia
Vancouver

Ontario
Brampton
Hamilton
Kitchener
London
Oshawa
Ottawa 
Toronto
 

34. A Study of MK-1084 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With KRASG12C Mutant Advanced Solid Tumors (MK-1084-001)

      ClinicalTrials.gov Identifier:              NCT05067283     
 
This study is currently recruiting participants.
 

This is a study evaluating the efficacy, safety, and pharmacokinetics of MK-1084 in participants with advanced solid tumors with identified kirsten rat sarcoma viral oncogene homolog G12C (KRASG12C) mutation and MK-1084 plus pembrolizumab in participants with first line (1L) non-small cell lung cancer (NSCLSC) with identified KRASG12C mutation.


Ontario
Hamilton
Toronto
 

35. Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab for NSCLC With KRAS G12C Mutation KRYSTAL-7

      ClinicalTrials.gov Identifier:              NCT04613596     
 
This study is currently recruiting participants.
 

This Phase 2 study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates for first-line treatment.


Ontario
Hamilton
Toronto